Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × 7-hydroxystaurosporine × Clear all
NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡